抑制A2AR可以缓解由腺介导的血细胞分化抑制
Paola Tieppo1, Hussein Shehade1, Chiara Martinoli1
1iTeos Therapeutics, Gosselies, Belgium.
Frontiers in immunology
|December 31, 2025
概括
高氨酸水平通过A2AR抑制B细胞通过A2AR成抗体分泌细胞 (ASC) 的成熟. A2AR对抗剂inupadenant完全逆转这种免疫抑制,恢复瘤中的ASC.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤微环境中的细胞外腺抑制免疫反应.
- 氨酸受体2A (A2AR) 在瘤透免疫细胞上表达,调解免疫抑制.
- B细胞和血细胞 (PCs) 对抗瘤免疫非常重要.
研究的目的:
- 研究A2AR在人类B细胞功能中的作用.
- 确定A2AR对抗对B细胞成熟和抗体产生的影响.
- 评估A2AR抗剂在癌症中的治疗潜力.
主要方法:
- 在瘤样本上进行定量质谱成像和GeoMx分析.
- 免疫组织化学,多重免疫光和scRNA-seq用于A2AR表达分析.
- 在体外和体内研究使用A2AR主动剂和对抗剂 (inupadenant) 在B细胞和瘤活检.
主要成果:
- 氨酸对PC频率产生负面影响,在B细胞,PC和血芽细胞 (ASC) 上具有高A2AR表达.
- 在体外,A2AR激活抑制了B细胞成长为ASC和免疫球蛋白的产生.
- 在体内,inupadenant治疗恢复了B细胞成熟,并在三级淋巴体结构中增加了ASC.
结论:
- 通过B细胞内在的机制,A2AR通过腺诱导的抑制B细胞成熟为ASCs.
- 伊努帕丹坦可以有效地逆转A2AR介导的免疫抑制.
- 准A2AR是一种有希望的策略,通过促进B细胞反应来增强抗瘤免疫力.
相关概念视频
Adrenergic Receptors: ɑ Subtype
2.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.3K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874


